Channing Capital Management LLC Has $12 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Channing Capital Management LLC boosted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.4% in the 4th quarter, Holdings Channel reports. The firm owned 50,764 shares of the medical research company’s stock after buying an additional 1,205 shares during the period. Channing Capital Management LLC’s holdings in Charles River Laboratories International were worth $12,001,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of CRL. abrdn plc lifted its position in shares of Charles River Laboratories International by 872.0% during the 4th quarter. abrdn plc now owns 121,807 shares of the medical research company’s stock worth $28,795,000 after buying an additional 109,275 shares during the last quarter. Regency Capital Management Inc. DE bought a new position in shares of Charles River Laboratories International in the fourth quarter worth about $3,703,000. WCM Investment Management LLC acquired a new stake in shares of Charles River Laboratories International in the 4th quarter valued at approximately $1,396,000. DekaBank Deutsche Girozentrale grew its holdings in shares of Charles River Laboratories International by 98.6% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 14,094 shares of the medical research company’s stock valued at $3,333,000 after purchasing an additional 6,997 shares during the last quarter. Finally, AMG National Trust Bank acquired a new position in Charles River Laboratories International during the 3rd quarter worth approximately $1,119,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Up 1.6 %

Shares of NYSE CRL traded up $3.58 during mid-day trading on Friday, reaching $233.47. 466,193 shares of the company’s stock traded hands, compared to its average volume of 482,082. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.52 and a quick ratio of 1.16. The business has a 50-day simple moving average of $252.23 and a 200 day simple moving average of $224.20. The stock has a market cap of $12.03 billion, a P/E ratio of 25.35, a PEG ratio of 1.83 and a beta of 1.44. Charles River Laboratories International, Inc. has a 1-year low of $161.65 and a 1-year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.39 by $0.07. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $991.25 million. During the same period in the previous year, the company posted $2.98 EPS. The company’s revenue for the quarter was down 7.9% on a year-over-year basis. On average, analysts expect that Charles River Laboratories International, Inc. will post 11.01 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on CRL. TheStreet raised shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a research note on Friday, March 1st. Guggenheim lowered Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Evercore ISI upped their target price on Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. JPMorgan Chase & Co. lifted their price target on Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. Finally, Citigroup upped their price objective on Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a research note on Thursday, February 15th. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and a consensus price target of $253.23.

Insider Activity at Charles River Laboratories International

In other news, VP William D. Barbo sold 4,050 shares of the stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total value of $1,006,425.00. Following the completion of the sale, the vice president now owns 22,879 shares in the company, valued at $5,685,431.50. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, EVP Victoria L. Creamer sold 5,000 shares of Charles River Laboratories International stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the sale, the executive vice president now directly owns 13,550 shares in the company, valued at $3,437,635. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP William D. Barbo sold 4,050 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total value of $1,006,425.00. Following the completion of the transaction, the vice president now owns 22,879 shares of the company’s stock, valued at approximately $5,685,431.50. The disclosure for this sale can be found here. In the last three months, insiders sold 14,932 shares of company stock valued at $3,693,663. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).